Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-TR1 · 1 trial · 2 indications
A DLT was defined as an AE occurring during Cycle 1(first 6 weeks of treatment) that was considered at least possibly related to study drug, was considered dose-dependent, and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr),Gr4 ntr of \>5 days' duration,increase(incr)of at least 1 gr from a preexisting Gr1 valvular insufficiency or any new Gr≥2 valvular toxicity,left ventricular(vtr) ejection fraction decrease of 10% in absolute value or 16% in relative value,incr in right vtr systolic pressure dysfunction from mild to moderate(mod) or from mod to severe,incr in left atrial or ventricular chamber size of ≥2 cm and ≥1cm respectively,any other life-threatening toxicity,significant morphologic on cardiac echocardiogram,any major ocular.
| Arm | Type | Description |
|---|---|---|
| IMC-TR1 | EXPERIMENTAL | Part A - Dose Escalation: Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles Part B - Disease Specific Cohort Expansion: Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose. |
| Name | Type | Description |
|---|---|---|
| IMC-TR1 | BIOLOGICAL | Administered intravenously |
Inclusion Criteria: * Part A and Part B: Participants must be appropriate candidates for experimental therapy, with a solid tumor that has failed standard therapy or for which no standard therapy is available, and evidence of progressive disease * Part A only: Participants must have histological...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
IMC-TR1 is an investigational monoclonal antibody being studied for the treatment of neoplasms, which are tumors. It was evaluated in a Phase 1 clinical trial in participants with advanced solid tumors. The drug is being developed by Eli Lilly and Company for use in oncology.
The specific molecular target of IMC-TR1 has not been disclosed in available information. As a monoclonal antibody, it is designed to interact with a specific protein involved in tumor growth, but the exact target is not publicly detailed. The drug is being investigated for its potential anti-tumor activity in advanced solid tumors.
IMC-TR1 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company conducted a Phase 1 clinical trial to evaluate the safety and tolerability of IMC-TR1 in patients with advanced solid tumors.
IMC-TR1 is in Phase 1 of clinical development. The Phase 1 trial, which has been completed, was an uncontrolled, non-randomized study that enrolled 14 participants with advanced solid tumors. The drug is investigational and has not been approved by regulatory authorities.
IMC-TR1 has been studied in one clinical trial, identified as NCT01646203, titled "A Study of IMC-TR1 in Participants With Advanced Solid Tumors." This Phase 1 trial was completed in the United States and enrolled 14 participants aged 18 years and older with neoplasms or tumors.
No alternative names for IMC-TR1 have been disclosed. The drug is known only by its code name IMC-TR1 in clinical trial records. It is a distinct investigational monoclonal antibody being developed by Eli Lilly and Company for the treatment of advanced solid tumors.